NCT05986682 · OUTCOME

Ophthalmology: Treatments for Ocular Toxicity

Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma · Source last updated 2025-02-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.

What was measured

Number of participants receiving treatment for ocular toxicity during BLENREP therapy, as categorized by type of treatment.

Groups in this outcome

Multiple Myeloma/Blenrep Participants

Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Multiple Myeloma/Blenrep Participants	30

Reported measurements

Received any Treatment for Ocular Toxicity

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma/Blenrep Participants	30	Not reported	Not reported	Not reported	Not reported

Encouraged Adherence to Eye Drop Regimen

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma/Blenrep Participants	15	Not reported	Not reported	Not reported	Not reported

Increased Eye Drops

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma/Blenrep Participants	10	Not reported	Not reported	Not reported	Not reported

Received a new prescription - Eye drops/ointment

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma/Blenrep Participants	11	Not reported	Not reported	Not reported	Not reported

Other

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Multiple Myeloma/Blenrep Participants	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
30
title
Received any Treatment for Ocular Toxicity
categories
measurements
group Id
OG000
value
15
title
Encouraged Adherence to Eye Drop Regimen
categories
measurements
group Id
OG000
value
10
title
Increased Eye Drops
categories
measurements
group Id
OG000
value
11
title
Received a new prescription - Eye drops/ointment
categories
measurements
group Id
OG000
value
1
title
Other

denoms

counts
group Id
OG000
value
30
units
Participants

description

Number of participants receiving treatment for ocular toxicity during BLENREP therapy, as categorized by type of treatment.

groups

description
Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023
id
OG000
title
Multiple Myeloma/Blenrep Participants

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.

title

Ophthalmology: Treatments for Ocular Toxicity

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice